Skip to main content

Peer Review reports

From: A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

Original Submission
24 May 2017 Submitted Original manuscript
30 Jul 2017 Reviewed Reviewer Report - Luigia Scudeller
4 Aug 2017 Reviewed Reviewer Report - Vichithranie Madurasinghe
28 Aug 2017 Reviewed Reviewer Report - Jenny Low
31 Aug 2017 Reviewed Reviewer Report - Jianfeng Xie
3 Sep 2017 Reviewed Reviewer Report - Juan Yepes
3 Sep 2017 Reviewed Reviewer Report - Judith-Irina Pagel
17 Nov 2017 Author responded Author comments - Jemal Hussein
Resubmission - Version 2
17 Nov 2017 Submitted Manuscript version 2
21 Nov 2017 Reviewed Reviewer Report - Judith-Irina Pagel
24 Nov 2017 Reviewed Reviewer Report - Luigia Scudeller
25 Nov 2017 Reviewed Reviewer Report - Jianfeng Xie
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
27 Nov 2017 Editorially accepted
10 Jan 2018 Article published 10.1186/s13063-017-2354-0

You can find further information about peer review here.

Back to article page